Anti-obesity (combination)
Naltrexone with bupropion
Brand names: Mysimba
Adult dose
Dose: Titrate over 4 weeks: 1 tab AM week 1 → 1 tab AM + PM week 2 → 2 tabs AM + 1 PM week 3 → 2 tabs AM + 2 PM week 4 onwards
Route: PO
Frequency: BD
Clinical pearls
- Adjunct to lifestyle for adults with BMI ≥30 (or ≥27 with comorbidity); NICE TA494
- Stop at 16 weeks if <5% weight loss
Contraindications
- Uncontrolled hypertension
- Seizure history / risk
- Bulimia/anorexia history
- Severe hepatic impairment
- Concurrent opioid use
- Concurrent MAOI / within 14 days
- Pregnancy
Side effects
- Nausea (very common)
- Constipation
- Headache
- Insomnia
- Hypertension
- Seizures
- Suicidal ideation
- Hepatotoxicity
Interactions
- MAOIs (avoid)
- Opioids
- CYP2B6 substrates
- Drugs lowering seizure threshold
- Strong CYP3A4 inhibitors
Monitoring
- BP
- HR
- Mental state
- LFTs
- Weight
Reference: BNF; NICE TA494; SmPC; https://bnf.nice.org.uk/drugs/naltrexone-with-bupropion/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016